Long-term follow-up of patients with birdshot retinochoroidopathy treated with systemic immunosuppression

Matthias D. Becker, Michael S. Wertheim, Justine R. Smith, James (Jim) Rosenbaum

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Purpose: Birdshot retinochoroidopathy (BRC) is a rare uveitis syndrome of presumed autoimmune etiology. Therapy with systemic and periocular corticosteroids is of inconsistent efficacy, attendant with numerous potential long-term side effects. Corticosteroid-sparing strategies with agents such as cyclosporine A or azathioprine have been suggested for this disease. Methods: We retrospectively reviewed the medical charts of patients with BRC who were evaluated consecutively at a tertiary-care, referral-based North American uveitis clinic over a 15-year period. Results: Eleven Caucasian patients (22 eyes) were diagnosed with BRC, representing approximately 1% of all cases seen at the uveitis clinic. HLA-A29 was positive in all 11 patients. We elected to treat five patients with azathioprine, methotrexate, cyclosporine A, mycophenolate mofetil, and/or IvIg, as well as systemic or periocular corticosteroid injections. The median period of follow-up for the five treated patients was six years (range: 8 months-13 years). Inflammation was reduced or stabilized in five of five patients. Conclusion: Although the definitive strategy for the management of BRC is unknown, control of intraocular inflammation and preservation of vision is possible with corticosteroid-sparing immunosuppressive agents.

Original languageEnglish (US)
Pages (from-to)289-293
Number of pages5
JournalOcular Immunology and Inflammation
Volume13
Issue number4
DOIs
StatePublished - Aug 2005

Fingerprint

Immunosuppression
Uveitis
Adrenal Cortex Hormones
Azathioprine
Cyclosporine
Intraocular Injections
Mycophenolic Acid
Inflammation
Tertiary Healthcare
Immunosuppressive Agents
Methotrexate
Referral and Consultation

Keywords

  • Birdshot syndrome
  • Immunosuppression
  • Uveitis

ASJC Scopus subject areas

  • Ophthalmology
  • Immunology and Allergy

Cite this

Long-term follow-up of patients with birdshot retinochoroidopathy treated with systemic immunosuppression. / Becker, Matthias D.; Wertheim, Michael S.; Smith, Justine R.; Rosenbaum, James (Jim).

In: Ocular Immunology and Inflammation, Vol. 13, No. 4, 08.2005, p. 289-293.

Research output: Contribution to journalArticle

@article{24415ebcb8184712b1adf2a3a38fca46,
title = "Long-term follow-up of patients with birdshot retinochoroidopathy treated with systemic immunosuppression",
abstract = "Purpose: Birdshot retinochoroidopathy (BRC) is a rare uveitis syndrome of presumed autoimmune etiology. Therapy with systemic and periocular corticosteroids is of inconsistent efficacy, attendant with numerous potential long-term side effects. Corticosteroid-sparing strategies with agents such as cyclosporine A or azathioprine have been suggested for this disease. Methods: We retrospectively reviewed the medical charts of patients with BRC who were evaluated consecutively at a tertiary-care, referral-based North American uveitis clinic over a 15-year period. Results: Eleven Caucasian patients (22 eyes) were diagnosed with BRC, representing approximately 1{\%} of all cases seen at the uveitis clinic. HLA-A29 was positive in all 11 patients. We elected to treat five patients with azathioprine, methotrexate, cyclosporine A, mycophenolate mofetil, and/or IvIg, as well as systemic or periocular corticosteroid injections. The median period of follow-up for the five treated patients was six years (range: 8 months-13 years). Inflammation was reduced or stabilized in five of five patients. Conclusion: Although the definitive strategy for the management of BRC is unknown, control of intraocular inflammation and preservation of vision is possible with corticosteroid-sparing immunosuppressive agents.",
keywords = "Birdshot syndrome, Immunosuppression, Uveitis",
author = "Becker, {Matthias D.} and Wertheim, {Michael S.} and Smith, {Justine R.} and Rosenbaum, {James (Jim)}",
year = "2005",
month = "8",
doi = "10.1080/09273940490912407",
language = "English (US)",
volume = "13",
pages = "289--293",
journal = "Ocular Immunology and Inflammation",
issn = "0927-3948",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Long-term follow-up of patients with birdshot retinochoroidopathy treated with systemic immunosuppression

AU - Becker, Matthias D.

AU - Wertheim, Michael S.

AU - Smith, Justine R.

AU - Rosenbaum, James (Jim)

PY - 2005/8

Y1 - 2005/8

N2 - Purpose: Birdshot retinochoroidopathy (BRC) is a rare uveitis syndrome of presumed autoimmune etiology. Therapy with systemic and periocular corticosteroids is of inconsistent efficacy, attendant with numerous potential long-term side effects. Corticosteroid-sparing strategies with agents such as cyclosporine A or azathioprine have been suggested for this disease. Methods: We retrospectively reviewed the medical charts of patients with BRC who were evaluated consecutively at a tertiary-care, referral-based North American uveitis clinic over a 15-year period. Results: Eleven Caucasian patients (22 eyes) were diagnosed with BRC, representing approximately 1% of all cases seen at the uveitis clinic. HLA-A29 was positive in all 11 patients. We elected to treat five patients with azathioprine, methotrexate, cyclosporine A, mycophenolate mofetil, and/or IvIg, as well as systemic or periocular corticosteroid injections. The median period of follow-up for the five treated patients was six years (range: 8 months-13 years). Inflammation was reduced or stabilized in five of five patients. Conclusion: Although the definitive strategy for the management of BRC is unknown, control of intraocular inflammation and preservation of vision is possible with corticosteroid-sparing immunosuppressive agents.

AB - Purpose: Birdshot retinochoroidopathy (BRC) is a rare uveitis syndrome of presumed autoimmune etiology. Therapy with systemic and periocular corticosteroids is of inconsistent efficacy, attendant with numerous potential long-term side effects. Corticosteroid-sparing strategies with agents such as cyclosporine A or azathioprine have been suggested for this disease. Methods: We retrospectively reviewed the medical charts of patients with BRC who were evaluated consecutively at a tertiary-care, referral-based North American uveitis clinic over a 15-year period. Results: Eleven Caucasian patients (22 eyes) were diagnosed with BRC, representing approximately 1% of all cases seen at the uveitis clinic. HLA-A29 was positive in all 11 patients. We elected to treat five patients with azathioprine, methotrexate, cyclosporine A, mycophenolate mofetil, and/or IvIg, as well as systemic or periocular corticosteroid injections. The median period of follow-up for the five treated patients was six years (range: 8 months-13 years). Inflammation was reduced or stabilized in five of five patients. Conclusion: Although the definitive strategy for the management of BRC is unknown, control of intraocular inflammation and preservation of vision is possible with corticosteroid-sparing immunosuppressive agents.

KW - Birdshot syndrome

KW - Immunosuppression

KW - Uveitis

UR - http://www.scopus.com/inward/record.url?scp=26944458573&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26944458573&partnerID=8YFLogxK

U2 - 10.1080/09273940490912407

DO - 10.1080/09273940490912407

M3 - Article

C2 - 16159719

AN - SCOPUS:26944458573

VL - 13

SP - 289

EP - 293

JO - Ocular Immunology and Inflammation

JF - Ocular Immunology and Inflammation

SN - 0927-3948

IS - 4

ER -